Jaguar Health, Inc. (JAGX) Financial Statements (2025 and earlier)

Company Profile

Business Address 200 PINE STREET SUITE 400
SAN FRANCISCO, CA 94104
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2025
MRQ
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments8,0026,4695,469 8,0903,495
Cash and cash equivalent8,0026,4695,469 8,0903,495
Restricted cash and investments      388
Receivables1,6472,1842,4672,1444,5601,695
Inventory, net of allowances, customer advances and progress billings10,3459,1897,0244,9002,7822,129
Inventory10,3459,1897,0244,9002,7822,129
Deferred costs    13  
Other undisclosed current assets12,20410,1217,36121,3772,3601,816
Total current assets:32,19827,96322,32128,43417,7929,522
Noncurrent Assets
Operating lease, right-of-use asset9361,1761,1401,084  
Property, plant and equipment464496557650677710
Intangible assets, net (including goodwill)18,47920,11622,43922,65124,33726,024
Intangible assets, net (excluding goodwill)18,47920,11622,43922,65124,33726,024
Other undisclosed noncurrent assets1,3481,01299544637154
Total noncurrent assets:21,22722,80025,13124,83125,05126,888
TOTAL ASSETS:53,42550,76347,45253,26542,84336,410
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities7,1978,77213,97312,0469,2528,274
Accounts payable5,2864,9745,8084,9294,7595,352
Accrued liabilities1,9113,7988,1657,1174,4932,922
Deferred revenue170     
Debt12,0384,86715,8833,1843,7897,115
Other undisclosed current liabilities2993484832411793
Total current liabilities:19,70413,98730,33915,47113,22015,392
Noncurrent Liabilities
Long-term debt and lease obligation23,50330,99317,74425,94112,421450
Long-term debt, excluding current maturities23,50330,99317,74425,02212,421450
Liabilities, other than long-term debt1,239886725   
Deferred revenue553     
Operating lease, liability686886725919  
Other undisclosed noncurrent liabilities    (919)  
Total noncurrent liabilities:24,74231,87918,46925,94112,421450
Total liabilities:44,44645,86648,80841,41225,64115,842
Temporary equity, including noncontrolling interest2,485     
Equity
Equity, attributable to parent, including:7,2854,954(657)11,60717,20210,674
Additional paid in capital354,234313,854266,971231,100184,090142,046
Accumulated other comprehensive loss(467)(652)(680)   
Accumulated deficit(346,482)(308,248)(266,948)(219,494)(166,899)(133,090)
Warrants and rights outstanding    1 3
Other undisclosed equity, attributable to parent     111,714
Equity, attributable to noncontrolling interest(791)(64)(699)242  
Other undisclosed equity  7 4 9,894
Total equity:6,4944,897(1,356)11,85317,20220,568
TOTAL LIABILITIES AND EQUITY:53,42550,76347,45253,26542,84336,410

Income Statement (P&L) ($ in thousands)

3/31/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Revenues11,689 11,956 9,3855,775
Cost of revenue(1,955)(2,037)(2,019)(2,333)(3,280)(3,816)
Gross profit:9,734(2,037)9,937(2,333)6,1051,959
Operating expenses(40,565)(42,015)(44,352)(41,076)(27,409)(30,259)
Other undisclosed operating income (loss) 9,761 2,701(5,343)(649)
Operating loss:(30,831)(34,291)(34,415)(40,708)(26,647)(28,948)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
51200950(765)19081
Interest and debt expense1,245(2,685)(14,910)(9,174)(4,656)(10,672)
Loss from continuing operations before equity method investments, income taxes:(29,535)(36,776)(48,375)(50,647)(31,113)(39,539)
Other undisclosed income (loss) from continuing operations before income taxes(9,716)(5,125)(20)(1,953)(2,696)1,009
Loss from continuing operations before income taxes:(39,251)(41,901)(48,395)(52,600)(33,809)(38,529)
Income tax expense      (10)
Loss from continuing operations:(39,251)(41,901)(48,395)(52,600)(33,809)(38,539)
Loss before gain (loss) on sale of properties:(52,600)(33,809)(38,539)
Net loss:(39,251)(41,901)(48,395)(52,600)(33,809)(38,539)
Net income attributable to noncontrolling interest7596019415  
Net loss available to common stockholders, diluted:(38,492)(41,300)(47,454)(52,595)(33,809)(38,539)

Comprehensive Income ($ in thousands)

3/31/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Net loss:(39,251)(41,901)(48,395)(52,600)(33,809)(38,539)
Other comprehensive income (loss)21731    
Other undisclosed comprehensive loss   (680)   
Comprehensive loss:(39,034)(41,870)(49,075)(52,600)(33,809)(38,539)
Comprehensive income, net of tax, attributable to noncontrolling interest7275989415  
Comprehensive loss, net of tax, attributable to parent:(38,307)(41,272)(48,134)(52,595)(33,809)(38,539)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: